conjugated equine estrogens (Premarin) Report issue

Animal product Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Combination drugs

( conjugated equine estrogens (Premarin), bazedoxifene (Duavee) )
|
( conjugated equine estrogens (Premarin), meprobamate (equanil) )
|
( conjugated equine estrogens (Premarin), medroxyprogesterone (provera) - other names: premphase, premphase (premarin;cycrin 14/14), prempro )

Alternative names

cenestin | conjugated equine estrogen | conjugated equine estrogens | conjugated estrogen | conjugated estrogens | conjugated oestrogens | estrogenic substances, conjugated | estrogens conjugated | estrogens,conjugated | estrogens, conjugated | estrogens, conjugated synthetic a | estrogens, conjugated synthetic b | oestrogens conjugated | oestrogens conjugated / bazedoxifene | premarin | premarin cream | synthetic conjugated estrogens | synthetic conjugated estrogens a | synthetic conjugated estrogens, a | synthetic conjugated estrogens, b

Organizations (87)

Research & Development (82)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (54)

Approved Indications (1)


 

Menopause (approved 1942)

Experimental Indications - Clinical Trial Phases 1-4 (54)


 

Amenorrhea (Phase 2)

Arteriosclerosis (Phase 4)

Arthralgia (Phase 2)

Atherosclerosis (Phase 2)

Atrophic Vaginitis (Phase 4)

Atrophy (Phase 3)

Blood Glucose (Phase 4)

Bone Diseases (Phase 3)

Brain Injuries, Traumatic (Phase 2)

Breast Neoplasms (Phase 3)

Cardiovascular Diseases (Phase 3)

Cognitive Dysfunction (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Cystocele (Phase 4)

Depression (Phase 4)

Diabetes Mellitus (Phase 3)

Endometrial Hyperplasia (Phase 4)

Endometrial Neoplasms (Phase 3)

Estrogen Replacement Therapy (Phase 1)

Estrogens (Phase 4)

General Surgery (Phase 4)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 3)

Hematuria (Phase 4)

Hormone Replacement Therapy (Phase 3)

Hot Flashes (Phase 3)

Hypercholesterolemia (Phase 3)

Hypertension (Phase 3)

Lupus Erythematosus, Systemic (Phase 4)

Menopause (Phase 4)

Metrorrhagia (Phase 1)

Myocardial Ischemia (Phase 3)

Obesity (Phase 4)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 1)

Parkinson Disease (Phase 2)

Pelvic Floor Disorders (Phase 4)

Pelvic Organ Prolapse (Phase 4)

Postmenopause (Phase 4)

Primary Ovarian Insufficiency (Phase 1)

Prostatic Neoplasms (Phase 2)

Reperfusion Injury (Phase 1/Phase 2)

Sexual Dysfunction, Physiological (Phase 4)

Shock, Hemorrhagic (Phase 2)

Thoracic Surgery (Phase 3)

Thrombosis (Phase 3)

Urinary Bladder, Overactive (Phase 4)

Urinary Tract Infections (Phase 4)

Uterine Diseases (Phase 2)

Uterine Prolapse (Phase 4)

Vaginal Diseases (Phase 3)

Vaginitis (Phase 4)

Vasomotor System (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 84
  • # of Trial Organizations: 82

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue